Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload
LV pressure overload increases myocardial susceptibility to anthracycline cardiotoxicity by inducing a high-energy-demand state. Anthracycline treatment, even at a low-risk dose, disrupts compensatory mechanisms in the pressure-overloaded heart, rapidly leading to cardiac dysfunction and heart failure. Preventive strategies targeting this metabolic vulnerability are urgently needed for patients with extant LV pressure overload (e.g. hypertension or valvular heart disease) who are undergoing anthracycline therapy.
Authors
- Carlos Galán‐Arriola (ORCID: https://orcid.org/0000-0001-7403-8974)
- Julien Ochala (ORCID: https://orcid.org/0000-0002-6358-2920)
- Antonio Molina (ORCID: https://orcid.org/0000-0002-5603-8492)
- Gonzalo J. López-Martín
- Javier D Sanchez-Gonzalez
- Inmaculada Jorge (ORCID: https://orcid.org/0000-0001-8645-9477)
- Laura Cádiz (ORCID: https://orcid.org/0000-0001-9212-7970)
- Jesús Vázquez
- Claudia Pérez-Martínez
- Carlos Caballero-Henares
- Víctor Bautista
- Danielle Medina-Hernández
- Borja Ibáñez
- Valentin Fuster
- Ali Ayaon-Albarrán
- Daniel Pérez-Camargo
Institutions
- University of Copenhagen (DK)
- Philips (Finland) (FI)
- Hospital Universitario La Paz (ES)
- Christus Health (US)
- Hospital Clínico San Carlos (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Mount Sinai Hospital (US)
- Centro de Investigación Biomédica en Red (ES)
- Christus Santa Rosa Health System (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Spanish National Centre for Cardiovascular Research (ES)
- Universidad Autónoma de Madrid (ES)
- Universidad de León (ES)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1093/eurheartj/ehaf1060
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39